Matches in Wikidata for { <http://www.wikidata.org/entity/Q97046794> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q97046794 description "clinical trial" @default.
- Q97046794 description "ensayo clínico" @default.
- Q97046794 description "ensayu clínicu" @default.
- Q97046794 description "klinisch onderzoek" @default.
- Q97046794 description "клінічне випробування" @default.
- Q97046794 description "临床试验" @default.
- Q97046794 name "A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease" @default.
- Q97046794 name "A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease" @default.
- Q97046794 type Item @default.
- Q97046794 label "A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease" @default.
- Q97046794 label "A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease" @default.
- Q97046794 prefLabel "A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease" @default.
- Q97046794 prefLabel "A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease" @default.
- Q97046794 P1132 Q97046794-3F4C2361-09CD-4FA1-B4FF-41F1440C4D53 @default.
- Q97046794 P1476 Q97046794-C3D9AA7F-3DD4-400B-81AB-0FE0C4BDBC7B @default.
- Q97046794 P17 Q97046794-6D0A3BA9-AF77-4A91-8236-43A80487A95E @default.
- Q97046794 P1813 Q97046794-EBDFF3F5-CC7D-4C23-A805-A06B799AE164 @default.
- Q97046794 P2899 Q97046794-1800BAF1-0F47-4824-B1A0-1B6E47D88788 @default.
- Q97046794 P3098 Q97046794-B537BE89-F983-4D2D-8DC8-826A1D4C0BE2 @default.
- Q97046794 P31 Q97046794-E34FA101-790F-4B6B-874C-F630FDFEDD9A @default.
- Q97046794 P4135 Q97046794-F110B366-EB50-4A5E-9F59-5B9FCA28D491 @default.
- Q97046794 P4844 Q97046794-EA37CD4F-4A66-4FF6-A1D6-32628980D31B @default.
- Q97046794 P580 Q97046794-E80D1CAF-59E3-4B7A-B79B-18A812BAD59A @default.
- Q97046794 P582 Q97046794-3E6EE17E-6FB8-48A2-8467-DC212AF149CF @default.
- Q97046794 P6099 Q97046794-79E0831A-B869-41CB-8301-518A2EB5F4C7 @default.
- Q97046794 P8005 Q97046794-4FD8AC96-3C7A-4E43-A03E-FF3D190B42CE @default.
- Q97046794 P8363 Q97046794-D9EF8D71-6E5D-472A-B03E-65ED20BF318B @default.
- Q97046794 P1132 "+216" @default.
- Q97046794 P1476 "An Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease" @default.
- Q97046794 P17 Q142 @default.
- Q97046794 P1813 "INFLAMMACOV" @default.
- Q97046794 P2899 "+18" @default.
- Q97046794 P3098 "NCT04424056" @default.
- Q97046794 P31 Q30612 @default.
- Q97046794 P4135 "+75" @default.
- Q97046794 P4844 Q415411 @default.
- Q97046794 P580 "2020-09-01T00:00:00Z" @default.
- Q97046794 P582 "2022-09-30T00:00:00Z" @default.
- Q97046794 P6099 Q42824827 @default.
- Q97046794 P8005 Q76649614 @default.
- Q97046794 P8363 Q78089383 @default.